Aberrant protein glycosylation : Implications on diagnosis and Immunotherapy
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
Glycosylation-mediated post-translational modification is critical for regulating many fundamental processes like cell division, differentiation, immune response, and cell-to-cell interaction. Alterations in the N-linked or O-linked glycosylation pattern of regulatory proteins like transcription factors or cellular receptors lead to many diseases, including cancer. These alterations give rise to micro- and macro-heterogeneity in tumor cells. Here, we review the role of O- and N-linked glycosylation and its regulatory function in autoimmunity and aberrant glycosylation in cancer. The change in cellular glycome could result from a change in the expression of glycosidases or glycosyltransferases like N-acetyl-glucosaminyl transferase V, FUT8, ST6Gal-I, DPAGT1, etc., impact the glycosylation of target proteins leading to transformation. Moreover, the mutations in glycogenes affect glycosylation patterns on immune cells leading to other related manifestations like pro- or anti-inflammatory effects. In recent years, understanding the glycome to cancer indicates that it can be utilized for both diagnosis/prognosis as well as immunotherapy. Studies involving mass spectrometry of proteome, site- and structure-specific glycoproteomics, or transcriptomics/genomics of patient samples and cancer models revealed the importance of glycosylation homeostasis in cancer biology. The development of emerging technologies, such as the lectin microarray, has facilitated research on the structure and function of glycans and glycosylation. Newly developed devices allow for high-throughput, high-speed, and precise research on aberrant glycosylation. This paper also discusses emerging technologies and clinical applications of glycosylation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Biotechnology advances - 66(2023) vom: 29. Sept., Seite 108149 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bangarh, Rashmi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Completed 09.06.2023 Date Revised 13.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biotechadv.2023.108149 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355352028 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355352028 | ||
| 003 | DE-627 | ||
| 005 | 20231226064151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biotechadv.2023.108149 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355352028 | ||
| 035 | |a (NLM)37030554 | ||
| 035 | |a (PII)S0734-9750(23)00056-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bangarh, Rashmi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aberrant protein glycosylation |b Implications on diagnosis and Immunotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.06.2023 | ||
| 500 | |a Date Revised 13.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Glycosylation-mediated post-translational modification is critical for regulating many fundamental processes like cell division, differentiation, immune response, and cell-to-cell interaction. Alterations in the N-linked or O-linked glycosylation pattern of regulatory proteins like transcription factors or cellular receptors lead to many diseases, including cancer. These alterations give rise to micro- and macro-heterogeneity in tumor cells. Here, we review the role of O- and N-linked glycosylation and its regulatory function in autoimmunity and aberrant glycosylation in cancer. The change in cellular glycome could result from a change in the expression of glycosidases or glycosyltransferases like N-acetyl-glucosaminyl transferase V, FUT8, ST6Gal-I, DPAGT1, etc., impact the glycosylation of target proteins leading to transformation. Moreover, the mutations in glycogenes affect glycosylation patterns on immune cells leading to other related manifestations like pro- or anti-inflammatory effects. In recent years, understanding the glycome to cancer indicates that it can be utilized for both diagnosis/prognosis as well as immunotherapy. Studies involving mass spectrometry of proteome, site- and structure-specific glycoproteomics, or transcriptomics/genomics of patient samples and cancer models revealed the importance of glycosylation homeostasis in cancer biology. The development of emerging technologies, such as the lectin microarray, has facilitated research on the structure and function of glycans and glycosylation. Newly developed devices allow for high-throughput, high-speed, and precise research on aberrant glycosylation. This paper also discusses emerging technologies and clinical applications of glycosylation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Glycosylation | |
| 650 | 4 | |a Metastasis | |
| 650 | 4 | |a Multi-omics | |
| 650 | 4 | |a glycans | |
| 650 | 4 | |a immunotherapy | |
| 650 | 7 | |a Glycosyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.4.- |2 NLM | |
| 650 | 7 | |a Lectins |2 NLM | |
| 650 | 7 | |a Polysaccharides |2 NLM | |
| 700 | 1 | |a Khatana, Chainika |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Simranjeet |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Anchita |e verfasserin |4 aut | |
| 700 | 1 | |a Kaushal, Ankur |e verfasserin |4 aut | |
| 700 | 1 | |a Siwal, Samarjeet Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Tuli, Hardeep Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Dhama, Kuldeep |e verfasserin |4 aut | |
| 700 | 1 | |a Thakur, Vijay Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Saini, Reena V |e verfasserin |4 aut | |
| 700 | 1 | |a Saini, Adesh K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biotechnology advances |d 1983 |g 66(2023) vom: 29. Sept., Seite 108149 |w (DE-627)NLM083784144 |x 1873-1899 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2023 |g day:29 |g month:09 |g pages:108149 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biotechadv.2023.108149 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2023 |b 29 |c 09 |h 108149 | ||